EntryPoint Capital’s Boston Scientific BSX Stock Holding History

EntryPoint Capital’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$231K	Hold	5,405	–	–	0.06%	642
2026 Q1	$339K	Sell	5,405 -2,643	-33%	-$211K	0.1%	418
2025 Q4	$767K	Buy	+8,048	New	+$789K	0.3%	61
2024 Q1	–	Sell	-165	Closed	-$9.54K	–	1445
2023 Q4	$9.54K	Buy	+165	New	+$8.81K	0.01%	1159

Other funds holding BSX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

EntryPoint Capital's BSX Position: Q2 2026 in Review

EntryPoint Capital held its Boston Scientific (BSX) position steady in Q2 2026 at 5,405 shares worth $231K. The position accounts for 0.06% of the portfolio, ranked #642.

EntryPoint Capital first reported a position in BSX in Q4 2023 and has held it in 4 quarters since. The position peaked at $767K in Q4 2025. 1,477 funds tracked by Wall St. Rank hold BSX as of Q2 2026.

EntryPoint Capital held 5,405 shares of Boston Scientific worth $231K as of Q2 2026.
EntryPoint Capital left its Boston Scientific share count unchanged in Q2 2026.
Boston Scientific made up 0.06% of EntryPoint Capital's portfolio in Q2 2026, its #642 holding.
EntryPoint Capital first reported a position in Boston Scientific in Q4 2023 and has held it in 4 quarters since.
EntryPoint Capital's Boston Scientific position peaked at $767K in Q4 2025.
1,477 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.

Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.